Innovating Works

MC

Desconocido
CHIRALFORCE: Chiral separation of molecules enabled by enantioselective optical forces in integrated nanophotonic... SYMERES NETHERLANDS BV participó en un HORIZON EUROPE: HORIZON-EIC-2021-PATHFINDEROPEN-01 Separating enantiomers is crucial to produce bio-active molecules, e.g., in early-phase drug discovery. CHIRALFORCE aims at a radically new...
2022-08-02 - 2026-05-31 | Financiado
BREAKthrough: Breaking the barrier - An integrated multidisciplinary approach to kill Gram-negative bacteria throu... SYMERES NETHERLANDS BV participó en un HORIZON EUROPE: HORIZON-MSCA-2021-DN-01 Antimicrobial resistance, which is caused by multi-drug-resistant bacterial pathogens is a global health emergency. Gram-negative bacteria (...
2022-07-14 - 2026-12-31 | Financiado
BiocatCodeExpander: Genetic code expansion for biocatalysis and enzyme engineering doctoral network SYMERES NETHERLANDS BV participó en un HORIZON EUROPE: HORIZON-MSCA-2021-DN-01 The expansion of the genetic code for the incorporation of non-canonical amino acids (NCAA) in proteins provides biotechnologists with an am...
2022-07-06 - 2026-12-31 | Financiado
ESCulab: European Screening Centre Unique Library for Attractive Biology SYMERES NETHERLANDS BV participó en un H2020: H2020-JTI-IMI2-2017-12-two-stage By bridging an important gap between basic research and drug development, ESCulab will facilitate the translation of fundamental scientific...
2018-12-18 - 2023-11-30 | Financiado
IT-DED3: Integrated Training in Dry Eye Disease Drug Development IT DED3 SYMERES NETHERLANDS BV participó en un H2020: H2020-MSCA-ITN-2017 The European network for Integrated Training in Dry Eye Disease Drug Development (IT-DED3) aims to deliver multidisciplinary and entrepreneu...
2017-08-17 - 2022-08-31 | Financiado
iDESIGN: Delivering Better Starting Points for Drug Discovery New Compound Libraries Driven By Intelligent D... SYMERES NETHERLANDS BV participó en un H2020: H2020-MSCA-ITN-2017 Whilst the need to generate new therapeutics has never been more important, drug discovery is at the same time becoming much more difficult....
2017-08-01 - 2021-12-31 | Financiado
EUC²LID: European Lead Factory SYMERES NETHERLANDS BV participó en un FP6: The European Lead Factory concept proposed by the EUC2LID Consortium relates to the discovery of novel small molecule candidates to serve as...
2013-01-01 - 2018-05-31 | Financiado
EUC²LID: European Lead Factory SYMERES NETHERLANDS BV participó en un FP7: The European Lead Factory concept proposed by the EUC2LID Consortium relates to the discovery of novel small molecule candidates to serve as...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.